Amity Institute of Pharmacy, Dipti Srivastava, Amity University Uttar Pradesh, Lucknow, India.
Amity Institute of Pharmacy, Zeeshan Fatima, Amity University Uttar Pradesh, Lucknow, India.
Mini Rev Med Chem. 2018;18(14):1160-1167. doi: 10.2174/1389557518666180305163613.
Cocrystallization is a technique for modifying the physicochemical and pharmacokinetic properties of an active pharmaceutical ingredient (API) embodying the concept of supramolecular synthon. Most of the examples cited in the literature are of cocrystals formed between an API and a coformer chosen from the generally recognized as safe (GRAS) substance list; however few examples exist where a cocrystal consists of two or more APIs. These cocrystals are commonly known as multi API, multi-drug or drug- drug cocrystals. The formation of such cocrystals is feasible by virtue of non covalent interactions between the APIs, which help them in retaining their activity. In addition, drugdrug cocrystals also offer potential solution to the limitations such as solubility, stability differences and chemical interaction between the APIs which is often faced during the traditional combination therapy. Cocrystallization of two or more APIs can be employed for delivery of combination drugs for the better and efficacious management of many complex disorders where existing monotherapies do not furnish the desired therapeutic effect. This review on the existing drug-drug cocrystals is to gain an insight for better designing of multi API cocrystals with improved physicochemical and pharmacokinetic profile and its application in multiple target therapy.
共晶化是一种用于改变活性药物成分 (API) 的物理化学和药代动力学性质的技术,体现了超分子合成子的概念。文献中引用的大多数示例都是在 API 和通常被认为是安全的 (GRAS) 物质列表中选择的共晶形成物之间形成的共晶;然而,只有少数示例存在由两个或更多 API 组成的共晶。这些共晶通常被称为多 API、多药物或药物-药物共晶。由于 API 之间的非共价相互作用,这些共晶的形成是可行的,这有助于它们保持其活性。此外,药物-药物共晶还为解决 API 之间的溶解度、稳定性差异和化学相互作用等限制提供了潜在的解决方案,这些限制在传统的联合治疗中经常出现。将两种或更多 API 共晶化可用于递送组合药物,以更好地有效管理许多复杂疾病,而现有单药治疗无法提供所需的治疗效果。对现有药物-药物共晶的综述旨在深入了解更好地设计具有改善的物理化学和药代动力学特性的多 API 共晶及其在多靶点治疗中的应用。